{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:36:41Z","timestamp":1792654601603,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this update, we review the recent discovery of autosomal recessive variants in sorbitol dehydrogenase as one of the commonest and potentially treatable causes of hereditary motor neuropathy and CMT2. We also report on recent therapeutic advances in hereditary neuropathy including the use of lipid nanoparticle sequestered antisense oligonucleotides in CMT1A and lipid nanoparticle delivered CRISPR-Cas9 gene editing in ATTR amyloidosis.<\/jats:p>","DOI":"10.1007\/s00415-022-11164-1","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T11:03:04Z","timestamp":1653130984000},"page":"5187-5191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Neurological update: hereditary neuropathies"],"prefix":"10.1007","volume":"269","author":[{"given":"Caroline","family":"Kramarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Rossor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"11164_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41588-020-0615-4","volume":"52","author":"A Cortese","year":"2020","unstructured":"Cortese A, Zhu Y, Rebelo AP et al (2020) Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes [published correction appears in Nat Genet. 2020 Jun;52(6):640]. Nat Genet 52:473\u2013481. https:\/\/doi.org\/10.1038\/s41588-020-0615-4","journal-title":"Nat Genet"},{"key":"11164_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamaneurol.2021.2598","volume":"78","author":"JO Johnson","year":"2021","unstructured":"Johnson JO, Chia R, Miller DE et al (2021) Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurol 78:1236\u20131248. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2598","journal-title":"JAMA Neurol"},{"key":"11164_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41591-021-01346-1","volume":"27","author":"P Mohassel","year":"2021","unstructured":"Mohassel P, Donkervoort S, Lone MA et al (2021) Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med 27:1197\u20131204. https:\/\/doi.org\/10.1038\/s41591-021-01346-1","journal-title":"Nat Med"},{"key":"11164_CR4","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1212\/WNL.0000000000006811","volume":"92","author":"V Fridman","year":"2019","unstructured":"Fridman V, Suriyanarayanan S, Novak P et al (2019) Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 92:e359\u2013e370. https:\/\/doi.org\/10.1212\/WNL.0000000000006811","journal-title":"Neurology"},{"key":"11164_CR5","doi-asserted-by":"publisher","first-page":"100345","DOI":"10.1016\/j.xcrm.2021.100345","volume":"2","author":"AJ Clark","year":"2021","unstructured":"Clark AJ, Kugathasan U, Baskozos G et al (2021) An iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ganglioside composition and axoglial interactions. Cell Rep Med. 2:100345. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100345","journal-title":"Cell Rep Med."},{"key":"11164_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s42003-021-01839-2","volume":"4","author":"S Boutary","year":"2021","unstructured":"Boutary S, Caillaud M, El Madani M et al (2021) Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of charcot\u2013marie\u2013tooth disease type 1 A. Commun Biol 4:317. https:\/\/doi.org\/10.1038\/s42003-021-01839-2","journal-title":"Commun Biol"},{"key":"11164_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J et al (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"11164_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/ene.14700","volume":"28","author":"M Frasquet","year":"2021","unstructured":"Frasquet M, Rojas-Garc\u00eda R, Argente-Escrig H et al (2021) Distal hereditary motor neuropathies: mutation spectrum and genotype-phenotype correlation [published correction appears in Eur J Neurol. 2022 Mar; 29(3):955]. Eur J Neurol 28:1334\u20131343. https:\/\/doi.org\/10.1111\/ene.14700","journal-title":"Eur J Neurol"},{"key":"11164_CR9","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1038\/s41598-021-86857-0","volume":"11","author":"P La\u0161\u0161uthov\u00e1","year":"2021","unstructured":"La\u0161\u0161uthov\u00e1 P, Mazanec R, Stan\u011bk D et al (2021) Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients. Sci Rep 11:8443. https:\/\/doi.org\/10.1038\/s41598-021-86857-0","journal-title":"Sci Rep"},{"key":"11164_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/acn3.51268","volume":"8","author":"RY Yuan","year":"2021","unstructured":"Yuan RY, Ye ZL, Zhang XR, Xu LQ, He J (2021) Evaluation of SORD mutations as a novel cause of Charcot\u2013Marie\u2013Tooth disease. Ann Clin Transl Neurol 8:266\u2013270. https:\/\/doi.org\/10.1002\/acn3.51268","journal-title":"Ann Clin Transl Neurol"},{"key":"11164_CR11","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.3390\/ijms22116048","volume":"22","author":"M Stavrou","year":"2021","unstructured":"Stavrou M, Sargiannidou I, Georgiou E, Kagiava A, Kleopa KA (2021) Emerging therapies for Charcot\u2013Marie\u2013Tooth inherited neuropathies. Int J Mol Sci 22:6048. https:\/\/doi.org\/10.3390\/ijms22116048","journal-title":"Int J Mol Sci"},{"key":"11164_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1389557515666150909143737","volume":"16","author":"AS Grewal","year":"2016","unstructured":"Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS (2016) Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem 16:120\u2013162. https:\/\/doi.org\/10.2174\/1389557515666150909143737","journal-title":"Mini Rev Med Chem"},{"key":"11164_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/archneur.60.3.329","volume":"60","author":"M Auer-Grumbach","year":"2003","unstructured":"Auer-Grumbach M, De Jonghe P, Verhoeven K et al (2003) Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol 60:329\u2013334. https:\/\/doi.org\/10.1001\/archneur.60.3.329","journal-title":"Arch Neurol"},{"key":"11164_CR14","first-page":"93","volume":"7","author":"MM Reilly","year":"2007","unstructured":"Reilly MM (2007) Sorting out the inherited neuropathies. Pract Neurol 7:93\u2013105","journal-title":"Pract Neurol"},{"key":"11164_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85817","volume":"27","author":"K Bejaoui","year":"2001","unstructured":"Bejaoui K, Wu C, Scheffler MD et al (2001) SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 27:261\u2013262. https:\/\/doi.org\/10.1038\/85817","journal-title":"Nat Genet"},{"key":"11164_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/85879","volume":"27","author":"JL Dawkins","year":"2001","unstructured":"Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA (2001) Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 27:309\u2013312. https:\/\/doi.org\/10.1038\/85879","journal-title":"Nat Genet"},{"key":"11164_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2018.05.008","volume":"117","author":"ER Wilson","year":"2018","unstructured":"Wilson ER, Kugathasan U, Abramov AY et al (2018) Hereditary sensory neuropathy type 1-associated deoxysphingolipids cause neurotoxicity, acute calcium handling abnormalities and mitochondrial dysfunction in vitro. Neurobiol Dis 117:1\u201314. https:\/\/doi.org\/10.1016\/j.nbd.2018.05.008","journal-title":"Neurobiol Dis"},{"key":"11164_CR18","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1074\/jbc.M109.092973","volume":"285","author":"A Penno","year":"2010","unstructured":"Penno A, Reilly MM, Houlden H et al (2010) Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 285:11178\u201311187. https:\/\/doi.org\/10.1074\/jbc.M109.092973","journal-title":"J Biol Chem"},{"key":"11164_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3988\/jcn.2007.3.2.101","volume":"3","author":"JH Lee","year":"2007","unstructured":"Lee JH, Kang HJ, Song H, Hwang SJ, Cho SY, Kim SB, Kim J, Chung KW, Choi BO (2007) A family harboring CMT1A duplication and HNPP deletion. J Clin Neurol 3:101\u2013104. https:\/\/doi.org\/10.3988\/jcn.2007.3.2.101","journal-title":"J Clin Neurol"},{"key":"11164_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13023-014-0201-x","volume":"9","author":"I Chumakov","year":"2014","unstructured":"Chumakov I, Milet A, Cholet N et al (2014) Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis. 9:201. https:\/\/doi.org\/10.1186\/s13023-014-0201-x","journal-title":"Orphanet J Rare Dis."},{"key":"11164_CR21","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/nm957","volume":"9","author":"MW Sereda","year":"2003","unstructured":"Sereda MW, Meyer Z, H\u00f6rste G, Suter U, Uzma N, Nave KA (2003) Therapeutic administration of progesterone antagonist in a model of Charcot\u2013Marie\u2013Tooth disease (CMT-1A). Nat Med 9:1533\u20131537. https:\/\/doi.org\/10.1038\/nm957","journal-title":"Nat Med"},{"key":"11164_CR22","doi-asserted-by":"publisher","first-page":"11952","DOI":"10.1002\/14651858.CD011952","volume":"2015","author":"B Gess","year":"2015","unstructured":"Gess B, Baets J, De Jonghe P, Reilly MM, Pareyson D, Young P (2015) Ascorbic acid for the treatment of Charcot\u2013Marie\u2013Tooth disease. Cochrane Database Syst Rev. 2015:11952. https:\/\/doi.org\/10.1002\/14651858.CD011952","journal-title":"Cochrane Database Syst Rev."},{"key":"11164_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","volume":"9","author":"S Attarian","year":"2014","unstructured":"Attarian S, Vallat JM, Magy L et al (2014) An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A [published correction appears in Orphanet J Rare Dis. 2016;11(1):92]. Orphanet J Rare Dis. 9:199. https:\/\/doi.org\/10.1186\/s13023-014-0199-0","journal-title":"Orphanet J Rare Dis."},{"key":"11164_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s13023-021-02040-8","volume":"16","author":"S Attarian","year":"2021","unstructured":"Attarian S, Young P, Brannagan TH et al (2021) A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot\u2013Marie\u2013Tooth type 1A. Orphanet J Rare Dis 16:433. https:\/\/doi.org\/10.1186\/s13023-021-02040-8","journal-title":"Orphanet J Rare Dis"},{"key":"11164_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"11164_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"11164_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1172\/JCI96499","volume":"128","author":"HT Zhao","year":"2018","unstructured":"Zhao HT, Damle S, Ikeda-Lee K et al (2018) PMP22 antisense oligonucleotides reverse Charcot\u2013Marie\u2013Tooth disease type 1A features in rodent models. J Clin Invest 128:359\u2013368. https:\/\/doi.org\/10.1172\/JCI96499","journal-title":"J Clin Invest"},{"key":"11164_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-019-0372-4","volume":"51","author":"A Cortese","year":"2019","unstructured":"Cortese A, Simone R, Sullivan R et al (2019) Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia [published correction appears in Nat Genet. 2019 May; 51(5):920]. Nat Genet 51:649\u2013658. https:\/\/doi.org\/10.1038\/s41588-019-0372-4","journal-title":"Nat Genet"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11164-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11164-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11164-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T15:12:46Z","timestamp":1660057966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11164-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["11164"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11164-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"22 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"This research was also supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. AMR is grateful to the BMA for the Vera Down Award and to the National Institute for Health Research University College London Hospitals Biomedical Research Centre. CK is supported by a UCL Queen Square Institute of Neurology and Cleveland Clinic London MPhil\/PhD Neuroscience fellowship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}